18.05.2011 | 110518_Epigenomics_AG_press_release_AGM Berlin, Germany, May 18, 2011 Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostics company, today issued invitations to its Annual General Shareholders’ Meeting scheduled for June 28, 2011.
18. May 2011
11. May 2011
11.05.2011 | 110511_Press_release_Q1_Results_ Berlin, Germany, May 11, 2011 – Epigenomics AG (Frankfurt Prime Standard: ECX) today reports its Q1 financials for the period ended 31 March 2011.
09. May 2011
Epigenomics AG: Screening More People for Colorectal Cancer with Septin9 Blood Tests Could Provide Medical Benefit and Be Cost-Effective
Health economic analysis in favor of Septin9 testing presented by renowned Stanford University researcher at Digestive Disease Week 2011
06. May 2011
Epigenomics AG: Life Technologies to Supply Crucial Components for Second-Generation Colorectal Cancer Blood Test
Berlin, Germany, and Seattle, WA, U.S.A., May 6, 2011 Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnosis company, today announced the signing of a supply agreement with Life Technologies Corporation, a global provider of innovative life science solutions. As the Original Equipment Manufacturer (OEM) Life Technologies will supply its Dynabeads® MyOne™ SILANE and buffers […]
20. April 2011
20.04.2011 | 110420_New_US_CEO_EN_final Berlin, Germany, and Seattle, WA, USA, April 20, 2011 Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer diagnosis company, today announced the appointment of Noel Doheny as the new Chief Executive Officer (CEO) of its subsidiary Epigenomics Inc. in Seattle, WA, USA, reporting to Geert Nygaard, CEO of Epigenomics AG. Mr. Doheny […]
07. April 2011
Continuing to build European market and expanding beyond. • Focus 2010/2011 on U.S. product development and FDA submission. • Launch of Epi proColon® 2.0 in Europe planned for 2011